MG-01(MG-01) - 在研适应症：过敏性哮喘，过敏性鼻炎，鼻结膜炎_专利_临床

概要

基本信息

药物类型

化学药

别名

靶点-

作用方式-

作用机制-

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 MG-01 相关的临床试验

NCT04891237

/ Recruiting临床3期

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass Pollen

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

开始日期2021-06-14

申办/合作机构

Inmunotek SL

NCT04898283

/ Recruiting临床3期

A RDPC, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of SCIT in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to Cupressaceae and Grasses.

A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.

开始日期2021-05-31

申办/合作机构

Inmunotek SL

NCT04874714

/ Terminated临床3期

Prospective, Randomized, Placebo-controlled, Multi-center Trial Comparing the Efficacy and Safety of Subcutaneous Immunotherapy With a Mixture of Grasses and Mites at Adequate Doses Versus Monotherapy, for the Treatment of Allergy

Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen

开始日期2021-04-30

申办/合作机构

Inmunotek SL

[+1]

100 项与 MG-01 相关的临床结果

登录后查看更多信息

100 项与 MG-01 相关的转化医学

登录后查看更多信息

100 项与 MG-01 相关的专利（医药）

登录后查看更多信息

100 项与 MG-01 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性哮喘	临床3期	西班牙	Inmunotek SL	2021-05-31
过敏性鼻炎	临床3期	西班牙	Inmunotek SL	2021-05-31
鼻结膜炎	临床3期	西班牙	Inmunotek SL	2021-04-30
过敏	临床前	西班牙	Inmunotek SL	2021-04-30
屋尘螨过敏	临床前	西班牙	Inmunotek SL	2021-04-30
常年性变应性鼻炎	临床前	西班牙	Inmunotek SL	2021-04-30
季节性过敏性鼻炎	临床前	西班牙	Inmunotek SL	2021-04-30